Last reviewed · How we verify
Per Os Acetaminophen
Acetaminophen reduces pain and fever by inhibiting prostaglandin synthesis in the central nervous system.
Acetaminophen reduces pain and fever by inhibiting prostaglandin synthesis in the central nervous system. Used for Mild to moderate pain, Fever reduction.
At a glance
| Generic name | Per Os Acetaminophen |
|---|---|
| Sponsor | Hospital for Special Surgery, New York |
| Drug class | Non-opioid analgesic and antipyretic |
| Target | Cyclooxygenase (COX), primarily in central nervous system |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Acetaminophen is a non-opioid analgesic and antipyretic that works primarily through inhibition of cyclooxygenase (COX) enzymes in the brain and spinal cord, reducing prostaglandin production. This leads to decreased pain perception and lowering of the body's temperature set point. The exact mechanism remains incompletely understood, but it does not significantly inhibit peripheral COX enzymes like NSAIDs do.
Approved indications
- Mild to moderate pain
- Fever reduction
Common side effects
- Hepatotoxicity (at high doses or chronic use)
- Rash
- Nausea
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- Jaw Muscle Pain Post Wisdom Molar Surgery (PHASE2)
- A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (PHASE2)
- Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD) (NA)
- Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) (PHASE3)
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Per Os Acetaminophen CI brief — competitive landscape report
- Per Os Acetaminophen updates RSS · CI watch RSS
- Hospital for Special Surgery, New York portfolio CI